# Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy

> **NCT00236951** · PHASE3 · COMPLETED · sponsor: **American Regent, Inc.** · enrollment: 224 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** iron sucrose injection USP
- **DRUG:** stable erythropoietin therapy

## Key facts

- **NCT ID:** NCT00236951
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-10
- **Final completion:** 2005-12
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2018-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236951, "Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00236951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*